EXCLUSIVE: SAB Biotherapeutics' Type 1 Diabetes Candidate Moves One Step Closer To Enter Human Trials With Completion Of Toxicology Study

SAB Biotherapeutics SABS has completed an IND-enabling GLP-tox study for SAB-142, further progressing the therapeutic to prevent and/or delay onset and progression of type 1 diabetes (T1D) and potentially other T-cell mediated autoimmune diseases. 

What Happened: The study assessed the toxicity and pharmacodynamic effects of SAB-142 at 1, 5, and 10 mg/kg doses against commercially available anti-thymocyte globulin at 5 mg/kg.

The candidate was well tolerated and showed a desired dose-dependent pharmacologic effect. SAB will submit the IND filing within approximately 12 months.

Also Read: SAB Biotherapeutics Unveils New Data From COVID-19 Programs Reinforcing Efficacy Against Variants.

The study results showed that both SAB-142 and the FDA-approved animal-derived polyclonal anti-thymocyte immunoglobulin induced transient lymphodepletion, confirming the SAB-142 mechanism. 

The depletion dynamics were more prolonged in the cohort with SAB-142 treatment.

In November, the company outlined data on SAB-185 for COVID-19 and SAB-176 for seasonal and pandemic influenza showing the candidates being effective against variants of several highly mutating viruses associated with the diseases.

Last week, SAB Biotherapeutics announced results from a project in collaboration with CSL, confirming that SAB's DiversitAb platform can generate functional fully-human anti-idiotype polyclonal antibodies that can effectively target and neutralize autoantibodies associated with autoimmune diseases.

Price Action: SABS shares closed at $0.68 on Monday.

Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsPenny StocksHealth CareMarket-Moving ExclusivesExclusivesGeneralPreclinical Phase
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!